Leading the next revolution for tackling diseases

At Avstera, our primary strength is leveraging key immunological cell insights to guide the development of promising novel therapeutics across a broad range of diseases. Our primary program is a highly selective oral HDAC6i immunomodulator IND-cleared to tackle tough to treat cancers. Our preclinical pipeline includes next-generation oral HDAC6i for cardiometabolic and cardiovascular indications. We aim to offer revolutionary easily administered solutions to address significant unmet needs for patients.